This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Labthavikul, P.
Right arrow Articles by Bradford, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Labthavikul, P.
Right arrow Articles by Bradford, P. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2003, p. 3967-3969, Vol. 47, No. 12
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.12.3967-3969.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of Tigecycline against Staphylococcus epidermidis Growing in an Adherent-Cell Biofilm Model

Pornpen Labthavikul, Peter J. Petersen,* and Patricia A. Bradford

Infectious Disease Research, Wyeth, Pearl River, New York 10965

Received 19 February 2003/ Returned for modification 3 July 2003/ Accepted 30 August 2003


arrow
ABSTRACT
 
The activity of tigecycline against Staphylococcus epidermidis growing in an in vitro adherent-cell biofilm model was determined. Tigecycline minimum bactericidal concentrations (MBCs) ranged from 1 to 8 µg/ml for S. epidermidis growing in a biofilm of adherent cells, compared to MBCs of 0.12 to >32 µg/ml for freely growing cells. The killing activity of tigecycline against the adherent bacteria was at least fourfold better than that of vancomycin and daptomycin.


arrow
TEXT
 
Staphylococcus epidermidis is a leading cause of medical-device-related infections, especially in immunocompromised patients. The treatment of these infections is further complicated by the emergence of multiresistant strains. The ability of S. epidermidis to form biofilms on smooth surfaces is believed to contribute significantly to the pathogenesis of these infections. Biofilms are notoriously difficult to eradicate and are often resistant to systemic antibiotic therapy. Numerous studies have reported S. epidermidis biofilm resistance to many antimicrobial agents in vitro and in vivo (2, 4, 5, 9, 10, 15, 16, 17).

Tigecycline (formerly GAR-936), a 9-glycylamido derivative of minocycline, is currently in phase III clinical trials. Tigecycline is a broad-spectrum antibacterial agent possessing excellent antimicrobial activity against most gram-positive pathogens, including S. epidermidis (1, 7, 13, 14). The goal of this study was to assess the antimicrobial activity of tigecycline against adherent S. epidermidis in an in vitro biofilm model.

(This work was presented in part previously [P. Labthavikul and P. A. Bradford, Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 525, 2000].)

Clinical isolates of S. epidermidis were screened for the ability to produce slime by a method described by Christensen et. al (3). The amount of slime production was scored, and the strains were categorized as strong, moderate, or weak slime producers or non-slime producers. The MICs and minimum bactericidal concentrations (MBCs) of tigecycline and the other antimicrobial agents against adherent S. epidermidis were determined as described previously (15, 16), with modifications. Bacterial suspensions (100 µl) at a density of 106 CFU/ml were made in phosphate-buffered saline supplemented with 0.25% glucose and were incubated in 96-well plates for 24 h at 37°C, without shaking, to allow the bacteria to attach to the surface. Nonadherent bacteria were removed by gentle washing two times with phosphate-buffered saline with a liquid-handling system (Cetus, Emeryville, Calif.). Serial twofold dilutions (100 µl per well) of antimicrobial agents in Mueller-Hinton broth (MHB II) were added to wells containing adherent cells. The plates were then incubated at 37°C for another 24 h. The MICadh was defined as the lowest concentration of antibiotic at which there was no observable bacterial growth in the wells containing adherent microcolonies. After the MICadhs were determined, the MHB II containing antibiotic was removed and replaced with 100 µl of antibiotic-free MHB II; this was followed by incubation for another 20 to 24 h at 37°C. The MBCadh was defined as the lowest concentration of antibiotic at which there was no bacterial growth following removal of the drug. All experiments with adherent cells were performed in duplicate. The MICs and MBCs of tigecycline and other antimicrobial agents for planktonic (freely growing) S. epidermidis were determined by broth microdilution assay as recommended by the NCCLS (11, 12) simultaneously with the adherent-cell experiments. To assess the possibility that the inoculum in the MIC tests with planktonic bacteria was substantially different from that of the adherent cells, colony counts were performed by plating representative planktonic and resuspended adherent isolates (see Table 2).


View this table:
[in this window]
[in a new window]
  		TABLE 2. Inoculum concentration of S. epidermidis

The MIC, MICadh, MBC, and MBCadh measurements obtained are summarized in Table 1. The MICs of most antibiotics for 90% of the strains tested (MIC90s) were comparable to the MIC90adhs. The MBC90 of the bactericidal antibiotic vancomycin (8 µg/ml) was fourfold lower than that of the bacteriostatic drugs tigecycline and minocycline (32 µg/ml) for freely growing cells. However, tigecycline and minocycline demonstrated more killing of adherent cells than did vancomycin and daptomycin (MBC90adhs, 8, 8, 32, and 32 µg/ml, respectively). The MBCadhs of vancomycin and daptomycin were higher than the MBC for planktonic bacteria by 2 to 3 dilutions. Tigecycline, minocycline, and teicoplanin demonstrated better activity against the biofilm bacteria than did the other comparative agents. The only agent that was slightly more active against adherent S. epidermidis (MBC90adh, 4 µg/ml) was the mannopeptimycin antibiotic AC98-6446, a novel semisynthetic glycopeptide under development at Wyeth (P. Labthavikul, P. J. Petersen, T. Z. Wang, R. G. Dushin, and P. A. Bradford, Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother., abstr. F355, 2002; R. G. Dushin and T. Z. Wang, Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother., abstr. F352, 2002). There was no correlation between the amount of slime produced by and the antibiotic susceptibility of strongly, moderately, and poorly slime-producing and non-slime-producing S. epidermidis bacteria. The colony counts from representative inocula used in the MIC tests with planktonic bacteria and bacteria recovered from resuspended adherent cells are shown in Table 2. For most of the strains, there was no significant difference between the inoculum used and the MICs determined with planktonic cells or adherent bacteria recovered from the wells. However, as expected, the colony counts of the two strains that did not produce slime were approximately 1 log lower than those of the adherent bacteria recovered from the wells.


View this table:
[in this window]
[in a new window]
  		TABLE 1. In vitro MICs and MBCs of tigecycline and comparative antibiotics against 68 planktonic and adherent S. epidermidis isolates

Biofilm is an assemblage of bacteria and a polysaccharide matrix (slime) that allows the bacteria to adhere to smooth surfaces and medical devices. The embedded bacteria are less accessible to antibiotics and the human immune system defense mechanism. None of the currently used bactericidal-compound-based technologies is completely effective at preventing microbial colonization of medical catheters (4, 6, 8, 10). In this study, we demonstrated that the bactericidal activities of tigecycline and minocycline against adherent S. epidermidis in a biofilm model were better than their activities against freely growing cells in that the MBC90adhs were lower than the MBC90s. Growth rate differences between adherent and planktonic cells have been indicated as a possible cause of susceptibility differences (2, 9, 10). This growth rate difference may have been a factor contributing to the better activity of tigecycline against adherent cells as well. The ability of tigecycline to inhibit the growth of adherent cells of S. epidermidis indicates that tigecycline is able to diffuse through the biofilm and act normally against its cellular target.

The findings of this in vitro study suggest that tigecycline might be considered for treatment of implant- or catheter-associated infections caused by slime-producing staphylococci. Although this model is lacking many of the components of a true in vivo biofilm, it is a good model with which to determine antibacterial activity against surface-associated bacteria. The relevance of any biofilm susceptibility testing to in vivo efficacy is still lacking. Therefore, further in vivo studies are warranted to confirm the efficacy of tigecycline against staphylococcal biofilm.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Infectious Disease Research, Wyeth Research, Bldg. 200, Rm. 3301, 401 N. Middletown Rd., Pearl River, NY 10965. Phone: (845) 602-3070. Fax: (845) 602-5671. E-mail: petersp{at}wyeth.com. Back


arrow
REFERENCES
 
    1
  1. Biedenbach, D. J., M. L. Beach, and R. N. Jones.2001 . In vitro antimicrobial activity of GAR-936 tested against antibiotic resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.Diagn. Microbiol. Infect. Dis. 40:173-177.[CrossRef][Medline]
    2. 2
  2. Brown, M. R., D. G. Allison, and P. Gilbert.1988 . Resistance of bacterial biofilms to antibiotics: a growth-rate related effect? J. Antimicrob. Chemother. 22:777-780.[Free Full Text]
    3. 3
  3. Christensen, G. D., W. A. Simpson, J. J. Younger, L. M. Baddour, F. F. Barrett, D. M. Melton, and E. H. Beachey. 1985. Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. J. Clin. Microbiol. 22:996-1006.[Abstract/Free Full Text]
    4. 4
  4. Danese, P. N. 2002. Antibiofilm approaches: prevention of catheter colonization. Chem. Biol. 9:873-880.[CrossRef][Medline]
    5. 5
  5. Drancourt, M., A. Stein, J. N. Argenson, A. Zannier, G. Curvale, and D. Raoult. 1993. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants.Antimicrob. Agents Chemother. 37:1214-1218.[Abstract/Free Full Text]
    6. 6
  6. Evans, R. C., and C. J. Holmes. 1987. Effect of vancomycin hydrochloride on Staphylococcus epidermidis biofilm associated with silicone elastomer.Antimicrob. Agents Chemother. 31:889-894.[Abstract/Free Full Text]
    7. 7
  7. Gales, A. C., and R. N. Jones. 2000. Antimicrobial activity and spectrum of the new glycylcycline GAR-936 tested against 1,203 recent clinical isolates. Diagn. Microbiol. Infect. Dis. 36:19-36.[CrossRef][Medline]
    8. 8
  8. Gilbert, P., P. J. Collier, and M. R. Brown.1990 . Influence of growth rate on susceptibility to antimicrobial agents: biofilms, cell cycle, dormancy, and stringent response. Antimicrob. Agents Chemother. 34:1865-1868.[Free Full Text]
    9. 9
  9. Holme, C. J., and R. C. Evans. 1989. Resistance of bacterial biofilms to antibiotics. J. Antimicrob. Chemother. 24:84-93.[Free Full Text]
    10. 10
  10. Lewis, K. 2001. Riddle of biofilm resistance.Antimicrob. Agents Chemother. 45:999-1007.[Free Full Text]
    11. 11
  11. NCCLS.1999 . Methods for determining bactericidal activity of antimicrobial agents, vol. 19. Approved guideline M26-A, NCCLS, Wayne, Pa.
    12. 12
  12. NCCLS.2000 . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed., vol. 20. Approved standard M7A5. NCCLS, Wayne, Pa.
    13. 13
  13. Petersen, P. J., N. V. Jacobus, W. J. Weiss, P. E. Sum, and R. T. Testa. 1999. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).Antimicrob. Agents Chemother. 43:738-744.[Abstract/Free Full Text]
    14. 14
  14. Petersen, P. J., P. A. Bradford, W. J. Weiss, T. M. Murphy, P. E. Sum, and S. J. Projan. 2002. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob. Agents Chemother. 46:2595-2601.[Abstract/Free Full Text]
    15. 15
  15. Souli, M., and H. Giamarellou. 1998. Effect of slime produced by clinical isolates of coagulase-negative staphylococci on activities of various antimicrobial agents. Antimicrob. Agents Chemother. 42:939-941.[Abstract/Free Full Text]
    16. 16
  16. Trafny, E. A. 1998. Susceptibility of adherent organisms from Pseudomonas aeruginosa and Staphylococcus aureus strains isolated from burn wounds to antimicrobial agents.Int. J. Antimicrob. Agents 10:223-228.[CrossRef][Medline]
    17. 17
  17. Yasuda, H., Y. Ajiki, T. Koga, and T. Yokota. 1994. Interaction between clarithromycin and biofilms formed by Staphylococcus epidermidis. Antimicrob. Agents Chemother. 38:138-141.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, December 2003, p. 3967-3969, Vol. 47, No. 12
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.12.3967-3969.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Martinez-Pastor, J. C., Munoz-Mahamud, E., Vilchez, F., Garcia-Ramiro, S., Bori, G., Sierra, J., Martinez, J. A., Font, L., Mensa, J., Soriano, A. (2009). Outcome of Acute Prosthetic Joint Infections Due to Gram-Negative Bacilli Treated with Open Debridement and Retention of the Prosthesis. Antimicrob. Agents Chemother. 53: 4772-4777 [Abstract] [Full Text]  
  • Vaudaux, P., Fleury, B., Gjinovci, A., Huggler, E., Tangomo-Bento, M., Lew, D. P. (2009). Comparison of Tigecycline and Vancomycin for Treatment of Experimental Foreign-Body Infection Due to Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 3150-3152 [Abstract] [Full Text]  
  • Flemming, K., Klingenberg, C., Cavanagh, J. P., Sletteng, M., Stensen, W., Svendsen, J. S., Flaegstad, T. (2009). High in vitro antimicrobial activity of synthetic antimicrobial peptidomimetics against staphylococcal biofilms. J Antimicrob Chemother 63: 136-145 [Abstract] [Full Text]  
  • Mascio, C. T. M., Alder, J. D., Silverman, J. A. (2007). Bactericidal Action of Daptomycin against Stationary-Phase and Nondividing Staphylococcus aureus Cells. Antimicrob. Agents Chemother. 51: 4255-4260 [Abstract] [Full Text]  
  • Ghiselli, R., Giacometti, A., Cirioni, O., Mocchegiani, F., Silvestri, C., Orlando, F., Kamysz, W., Licci, A., Nadolski, P., Della Vittoria, A., Lukasiak, J., Scalise, G., Saba, V. (2007). Pretreatment With the Protegrin IB-367 Affects Gram-Positive Biofilm and Enhances the Therapeutic Efficacy of Linezolid in Animal Models of Central Venous Catheter Infection. JPEN J Parenter Enteral Nutr 31: 463-468 [Abstract] [Full Text]  
  • Raad, I., Hanna, H., Jiang, Y., Dvorak, T., Reitzel, R., Chaiban, G., Sherertz, R., Hachem, R. (2007). Comparative Activities of Daptomycin, Linezolid, and Tigecycline against Catheter-Related Methicillin-Resistant Staphylococcus Bacteremic Isolates Embedded in Biofilm. Antimicrob. Agents Chemother. 51: 1656-1660 [Abstract] [Full Text]  
  • Aslam, S., Trautner, B. W., Ramanathan, V., Darouiche, R. O. (2007). Combination of Tigecycline and N-Acetylcysteine Reduces Biofilm-Embedded Bacteria on Vascular Catheters. Antimicrob. Agents Chemother. 51: 1556-1558 [Abstract] [Full Text]  
  • Olson, M. W., Ruzin, A., Feyfant, E., Rush, T. S. III, O'Connell, J., Bradford, P. A. (2006). Functional, biophysical, and structural bases for antibacterial activity of tigecycline.. Antimicrob. Agents Chemother. 50: 2156-2166 [Abstract] [Full Text]  
  • Giacometti, A., Cirioni, O., Ghiselli, R., Orlando, F., Mocchegiani, F., Silvestri, C., Licci, A., De Fusco, M., Provinciali, M., Saba, V., Scalise, G. (2005). Comparative Efficacies of Quinupristin-Dalfopristin, Linezolid, Vancomycin, and Ciprofloxacin in Treatment, Using the Antibiotic-Lock Technique, of Experimental Catheter-Related Infection Due to Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 4042-4045 [Abstract] [Full Text]  
  • Pankey, G. A. (2005). Tigecycline. J Antimicrob Chemother 56: 470-480 [Abstract] [Full Text]  
  • Pettit, R. K., Weber, C. A., Kean, M. J., Hoffmann, H., Pettit, G. R., Tan, R., Franks, K. S., Horton, M. L. (2005). Microplate Alamar Blue Assay for Staphylococcus epidermidis Biofilm Susceptibility Testing. Antimicrob. Agents Chemother. 49: 2612-2617 [Abstract] [Full Text]  
  • Sun, H. K., Ong, C. T., Umer, A., Harper, D., Troy, S., Nightingale, C. H., Nicolau, D. P. (2005). Pharmacokinetic Profile of Tigecycline in Serum and Skin Blister Fluid of Healthy Subjects after Multiple Intravenous Administrations. Antimicrob. Agents Chemother. 49: 1629-1632 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Labthavikul, P.
Right arrow Articles by Bradford, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Labthavikul, P.
Right arrow Articles by Bradford, P. A.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»